Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 45 - Medicinal preparations containing active ingredients not provided for in groups
Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020)
04/1999
04/28/1999EP0910410A1 Topical composition comprising a combination of antihistaminic compounds with terpenoid compounds
04/28/1999EP0910408A1 DELIVERY SYSTEM USING mAb 3E10 AND MUTANTS AND/OR FUNCTIONAL FRAGMENTS THEREOF
04/28/1999EP0910403A1 Stationary phase, stress response sigma factor from mycobacterium tuberculosis, and regulation thereof
04/28/1999EP0910401A1 Compounds that inhibit the binding of raf-1 or 14-3-3 proteins to the beta chain of il-2 receptor, and pharmaceutical compositions containing same
04/28/1999EP0910400A1 Therapies for chronic renal failure
04/28/1999EP0910397A1 Vascular irrigation solution and method for inhibition of pain, inflammation, spasm and restenosis
04/28/1999EP0910386A1 Combinations comprising vx478, zidovudine and/or 1592u89 for use in the treatment of hiv
04/28/1999EP0910385A1 Sensitization of cells to radiation and chemotherapy
04/28/1999EP0910382A1 Treatment of carcinomas using squalamine in combination with other anti-cancer agents
04/28/1999EP0910377A1 Anti-vaginitis composition for topical use comprising one or more anti-vaginitis medicaments and one or more local anaesthetics
04/28/1999EP0910376A2 Use of clotrimazole and related compounds in the treatment of diarrhea
04/28/1999EP0910365A1 Growth inhibition and eradication of solid tumors using neuroendocrine resetting therapy and photodynamic therapy
04/28/1999EP0910362A1 Oxa acids and related compounds for treating skin conditions
04/28/1999EP0910361A1 Use of an osmolyte for treating the effects of an infection, an inflammation or an immune dysfunction
04/28/1999EP0910360A1 Reduction of cardiotoxicity of an antitumor agent using manganese compound
04/28/1999EP0910357A1 Down-regulation of dna repair to enhance sensitivity to p53-mediated suppression
04/28/1999EP0650361B1 Compositions for the treatment of arthritis containing phosphonates and nsaids
04/28/1999EP0295248B2 Liposome preparation and antibiotic
04/28/1999CN1215340A Composition comprising interleukin-1 inhibitor and controlled release polymer
04/28/1999CN1215338A Pharmaceutical combination containing a compound having angiotensin II and antagonisti activity
04/28/1999CN1215309A Implantable agarose-collagen beads containing cells which produce a diffusible biological product, and uses thereof
04/28/1999CA2248274A1 Novel dbpa
04/27/1999US5898038 Administering nitroglycerine and a bisphosphonate selected from disodium etidronate, pamidronate, clodronate, residronate or alendronate to the patient suffering from primary and secondary osteoprosis
04/27/1999US5898035 A pharmaceutical formulation for the intravenous regional sympathetic blockade treatment comprising an adrenergic blocking agent and pain reliever for reducing hypotensive side-effect
04/27/1999US5898033 Antiinflammatory non-immunogenic conjugate comprising polyamino acid backbone having multiplicity of molecules of non-steroidal antiinflammatory agent linked thereto, which is preferentially internalized by antigen-processing cells
04/27/1999CA2248119A1 Novel apt
04/27/1999CA2248116A1 Novel muty
04/27/1999CA2129635C Method of ophthalmic drug delivery
04/27/1999CA2064585C Inhibition of tumor growth by blockade of the protein c system
04/24/1999CA2248170A1 A clone hwhhj20
04/23/1999CA2245997A1 Novel compounds
04/22/1999WO1999019496A1 Inhibition of human immunodeficiency virus (hiv-1) replication
04/22/1999WO1999019486A1 Cell division regulators
04/22/1999WO1999019483A1 Human progesterone receptor complex p23-like protein
04/22/1999WO1999019481A2 Mammalian genes involved in viral infection and tumor suppression
04/22/1999WO1999019478A1 Agonist and antagonist peptides of carcinoembryonic antigen (cea)
04/22/1999WO1999019477A1 Cadherin derived growth factor and the application thereof
04/22/1999WO1999019473A1 Transgenic animal models for cardiac hypertrophy and uses thereof
04/22/1999WO1999019471A1 Models and treatments for cardiac hypertrophy in relation with nf-at3 function
04/22/1999WO1999019354A1 Novel vitamin d receptor related polypeptides, nucleic acid sequence encoding the same and uses thereof
04/22/1999WO1999018997A1 Potentiator for antibody against lymphoid tumor
04/22/1999WO1999018967A1 Analgesic compositions
04/22/1999WO1999018961A1 Method of preventing nephrotoxicity caused by cyclosporins and tacrolimus
04/22/1999WO1999018960A1 Novel combination
04/22/1999WO1999018953A1 Flavonoids for cystic fibrosis therapy
04/22/1999WO1999018952A1 UPREGULATION OF TYPE III ENDOTHELIAL CELL NITRIC OXIDE SYNTHASE BY HMG-CoA REDUCTASE INHIBITORS
04/22/1999WO1999018949A1 Nitric oxide donor compositions, methods, apparatus, and kits for preventing or alleviating vasoconstriction or vasospasm in a mammal
04/22/1999WO1999018944A1 Use of thiazolidinediones for the treatment of hyperglycaemia
04/22/1999WO1999018943A1 Use of thiazolidinediones for the treatment of hyperglycaemia
04/22/1999WO1999018942A1 Use of csaidtm compounds for the management of uterine contractions
04/22/1999WO1999018941A2 Ih-MODULATORS
04/22/1999WO1999018938A1 Delayed total release gastrointestinal drug delivery system
04/22/1999WO1999018935A1 Preparation of a directly mouldable tabletting auxiliary
04/22/1999WO1999018814A1 Preparation for the enhancement of the antioxidant status of cells
04/22/1999WO1999018798A1 Compositions and methods for the treatment of primary and metastatic neoplastic diseases using arsenic compounds
04/22/1999WO1999018794A1 Method for treating alzheimer's disease
04/22/1999WO1999013886B1 Multiple target hybridizing nucleic acids, their preparation, compositions, formulation, kits and applications
04/22/1999WO1999006035A3 COMBINATIONS OF HMG-CoA REDUCTASE INHIBITORS AND NICOTINIC ACID COMPOUNDS AND METHODS FOR TREATING HYPERLIPIDEMIA ONCE A DAY AT NIGHT
04/22/1999WO1999002565A3 Agent for the treatment and/or prophylaxis of microcirculation disorders
04/22/1999WO1999001118A3 Antioxidant enhancement of therapy for hyperproliferative conditions
04/22/1999WO1998044021A9 Biodegradable terephthalate polyester-poly(phosphate) polymers, compositions, articles, and methods for making and using the same
04/22/1999DE19845339A1 Directly compressible tabletting aid
04/22/1999CA2696653A1 Mammalian genes involved in viral infection and tumor suppression
04/22/1999CA2316296A1 Use of csaidtm compounds for the management of uterine contractions
04/22/1999CA2315244A1 Transgenic animal models for cardiac hypertrophy and uses thereof
04/22/1999CA2307929A1 Upregulation of type iii endothelial cell nitric oxide synthase by hmg-coa reductase inhibitors
04/22/1999CA2307328A1 Cell division regulators
04/22/1999CA2307208A1 Compositions and methods for the treatment of primary and metastatic neoplastic diseases using arsenic compounds
04/22/1999CA2306453A1 Novel vitamin d receptor related polypeptides, nucleic acid sequence encoding the same and uses thereof
04/22/1999CA2306448A1 Models and treatments for cardiac hypertrophy in relation with nf-at3 function
04/22/1999CA2306444A1 Inhibition of human immunodeficiency virus (hiv-1) replication
04/22/1999CA2306096A1 Nitric oxide donor compositions, methods, apparatus, and kits for preventing or alleviating vasoconstriction or vasospasm in a mammal
04/22/1999CA2306086A1 Use of thiazolidinediones for the treatment of hyperglycaemia
04/22/1999CA2305698A1 Human progesterone receptor complex p23-like protein
04/22/1999CA2305289A1 Use of thiazolidinediones for the treatment of hyperglycaemia
04/22/1999CA2305262A1 Method for treating alzheimer's disease
04/22/1999CA2305180A1 Ih-modulators
04/22/1999CA2305141A1 Novel combination
04/22/1999CA2304374A1 Method of preventing nephrotoxicity caused by cyclosporins and tacrolimus
04/21/1999EP0909820A2 Histidine kinase from Staphylococcus pneumoniae
04/21/1999EP0909560A2 Treatment o tumors with compounds having RXR retinoid receptor agoinst activity
04/21/1999EP0909559A2 Use of inhibitors of the sodium hydrogen exchange in the manufacture of a medicament for treatment or prophylaxis of diseases of the central nervous system
04/21/1999EP0909181A1 Novel compounds
04/21/1999EP0909180A1 Novel compounds
04/21/1999EP0909174A1 TREATMENT OF CYSTIC DISEASE WITH TNF-$g(a)
04/21/1999EP0909169A1 Medical use
04/21/1999CN1214682A Eprosartan dihydrate and process for its production and formulation
04/21/1999CN1214630A Photopheresis treatment of leukocytes
04/21/1999CN1214629A Solid instant-release forms of administration and process for producing the same
04/20/1999US5895663 Pseudoephedrine hydrochloride extended-release tablets
04/20/1999US5895660 Deuterated active substances in transdermal application
04/20/1999US5895652 Method of metabolic adjuvanation and cellular repair
04/20/1999US5895649 Method for treating neurogenic red skin blotches with compositions containing TNF-alpha antagonists
04/15/1999WO1999018432A1 Methods for screening drugs to predict tardive dyskinesia
04/15/1999WO1999018213A1 MUTANTS OF YEAST Cdc24p, DEFECTIVE IN BINDING OF THE G-PROTEIN BETA SUBUNIT
04/15/1999WO1999018193A1 Jnk3 modulators and methods of use
04/15/1999WO1999018191A1 Transgenic animals with knocked-in vec receptor genes and uses thereof
04/15/1999WO1999018187A1 NOVEL clpL
04/15/1999WO1999018142A1 BIODEGRADABLE LOW MOLECULAR WEIGHT TRIBLOCK POLY(LACTIDE-co-GLYCOLIDE) POLYETHYLENE GLYCOL COPOLYMERS HAVING REVERSE THERMAL GELATION PROPERTIES
04/15/1999WO1999018117A1 3-hydroxyacyl-coa dehydrogenase from staphylococcus aureus
1 ... 1022 1023 1024 1025 1026 1027 1028 1029 1030 1031 1032 1033 1034 1035 1036 1037 1038 1039 1040 1041 1042 ... 1151